leading oncologists, hematologists, and nephrologists comprehensively review the role of hgfs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. the authors focus on the use of hgfs in oncology, describing their cutting-edge application to patients with lung cancer, hodgkins and nonhodgkins lymphoma, breast cancer, chronic lymphocytic leukemia, aids-related malignancies, myelodysplastic syndromes, and aplastic anemias. among the hgfs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem cell factor and its receptor, c-kit. to complete their survey, the contributors also consider the safety and economic implications of hgfs and the future potential for hgf antagonists in oncology.